These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 37391283

  • 21. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
    Morote J, Campistol M, Regis L, Celma A, de Torres I, Semidey ME, Roche S, Mast R, Santamaria A, Planas J, Trilla E.
    Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
    [Abstract] [Full Text] [Related]

  • 22. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.
    Kwe J, Baunacke M, Boehm K, Platzek I, Thomas C, Borkowetz A.
    World J Urol; 2024 Feb 16; 42(1):84. PubMed ID: 38363332
    [Abstract] [Full Text] [Related]

  • 23. Unlocking Precision Enhancing Prostate Cancer Detection and Reducing Unnecessary Biopsies with Combined Prostate-Specific Antigen Density and PI-RADS Score.
    Hamidi N, Uzel T, Demirci A, Basar H.
    J Coll Physicians Surg Pak; 2024 Oct 16; 34(10):1205-1210. PubMed ID: 39410690
    [Abstract] [Full Text] [Related]

  • 24. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
    Singh S, Rogers H, Kanber B, Clemente J, Pye H, Johnston EW, Parry T, Grey A, Dinneen E, Shaw G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Giganti F, Atkinson D, Moore CM, Whitaker HC, Alexander DC, Panagiotaki E, Punwani S.
    Radiology; 2022 Dec 16; 305(3):623-630. PubMed ID: 35916679
    [No Abstract] [Full Text] [Related]

  • 25. Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions.
    Ajami T, Han S, Porto JG, Kimbel I, Szczotka Z, Guerard T, VanderVeer-Harris N, Ledesma BR, Acosta PC, Kryvenko ON, Parekh DJ, Stoyanova R, Reis IM, Punnen S.
    Urol Oncol; 2024 Nov 16; 42(11):370.e9-370.e14. PubMed ID: 38971674
    [Abstract] [Full Text] [Related]

  • 26. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
    Leow JJ, Koh SH, Chow MW, Loke W, Salada R, Hong SK, Yeow Y, Lee CH, Tan CH, Tan TW.
    Asian J Androl; 2023 Nov 16; 25(1):43-49. PubMed ID: 35488666
    [Abstract] [Full Text] [Related]

  • 27. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
    Kim M, Ryu H, Lee HJ, Hwang SI, Choe G, Hong SK.
    World J Urol; 2021 May 16; 39(5):1463-1471. PubMed ID: 32696126
    [Abstract] [Full Text] [Related]

  • 28. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF.
    Clin Genitourin Cancer; 2020 Dec 16; 18(6):e698-e704. PubMed ID: 32493676
    [Abstract] [Full Text] [Related]

  • 29. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S, Neves Alberto J, Carvalho Dias E, Sousa Passos P, Cerqueira Alves M.
    Arch Ital Urol Androl; 2022 Mar 28; 94(1):32-36. PubMed ID: 35352522
    [Abstract] [Full Text] [Related]

  • 30. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Deniffel D, Perlis N, Ghai S, Girgis S, Healy GM, Fleshner N, Hamilton R, Kulkarni G, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA.
    Eur Radiol; 2022 Nov 28; 32(11):7544-7554. PubMed ID: 35507051
    [Abstract] [Full Text] [Related]

  • 31. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
    Haack M, Miksch V, Tian Z, Duwe G, Thomas A, Borkowetz A, Stroh K, Thomas C, Haferkamp A, Höfner T, Boehm K.
    World J Urol; 2022 Dec 28; 40(12):2947-2954. PubMed ID: 36318314
    [Abstract] [Full Text] [Related]

  • 32. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C, Liu SL, Wang ZX, Yu K, Feng CX, Ke Z, Wang L, Zeng XY.
    Asian J Androl; 2018 Dec 28; 20(5):459-464. PubMed ID: 29667616
    [Abstract] [Full Text] [Related]

  • 33. One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.
    Tafuri A, Ashrafi AN, Palmer S, Shakir A, Cacciamani GE, Iwata A, Iwata T, Cai J, Sali A, Gupta C, Medina LG, Stern MC, Duddalwar V, Aron M, Gill IS, Abreu A.
    World J Urol; 2020 Apr 28; 38(4):949-956. PubMed ID: 31175460
    [Abstract] [Full Text] [Related]

  • 34. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Girometti R, Giannarini G, Panebianco V, Maresca S, Cereser L, De Martino M, Pizzolitto S, Pecoraro M, Ficarra V, Zuiani C, Valotto C.
    Br J Radiol; 2022 Mar 01; 95(1131):20210886. PubMed ID: 34762506
    [Abstract] [Full Text] [Related]

  • 35. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F, Stabile A, Mazzone E, Brembilla G, Sorce G, Pellegrino F, Scuderi S, Cannoletta D, Cirulli GO, Cucchiara V, Gandaglia G, De Cobelli F, Montorsi F, Briganti A.
    Urol Oncol; 2022 Mar 01; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [Abstract] [Full Text] [Related]

  • 36. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, Shariat SF, Pinker K, Helbich TH, Baltzer PAT.
    Clin Radiol; 2020 Feb 01; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [Abstract] [Full Text] [Related]

  • 37. Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men With Prostate-specific Antigen Level 4 to 10 ng/mL: Importance of Lesion Location.
    Chen Y, Ruan M, Zhou B, Hu X, Wang H, Liu H, Liu J, Song G.
    Clin Genitourin Cancer; 2021 Aug 01; 19(4):288-295. PubMed ID: 33632569
    [Abstract] [Full Text] [Related]

  • 38. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
    Haj-Mirzaian A, Burk KS, Lacson R, Glazer DI, Saini S, Kibel AS, Khorasani R.
    JAMA Netw Open; 2024 Mar 04; 7(3):e244258. PubMed ID: 38551559
    [Abstract] [Full Text] [Related]

  • 39. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
    Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, Chen J, Yang W, Ma S, Wu P, Jing Y, Wen W, Kang F, Wang J, Qin W.
    Prostate Cancer Prostatic Dis; 2024 Jun 04; 27(2):288-293. PubMed ID: 38160227
    [Abstract] [Full Text] [Related]

  • 40. PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
    Falkenbach F, Ambrosini F, Kachanov M, Ortner G, Maurer T, Köhler D, Beyersdorff D, Graefen M, Budäus L.
    World J Urol; 2024 Mar 20; 42(1):182. PubMed ID: 38506941
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.